The decarboxylation of DOPA by erythrocyte hemolysates differs from DOPA decarboxylation catalyzed by aromatic aminoacid decarboxylases that contain vitamin B6 in several significant respects. The ability of erythrocyte hemolysates to decarboxylate DOPA is associated with interaction between DOPA and methemoglobin; the ferriheme protein is reduced and DOPA is decarboxylated, probably after oxidation to a quinone intermediate. An analogous reaction takes place between DOPA a-nd other ferriheme proteins, such as metmyoglobin and cytochrome c. This phenomenon may be of significance in relation to the side effects observed in patients with Parkinson's disease who are treated with very large doses of DOPA.
Recent studies in this laboratory showed that DOPA is decarboxylated by-hemolysates of human erythrocytes (1) . We have further investigated this phenomenon and have found that this reaction is different from that catalyzed by the typical aromatic aminoacid decarboxylases found in liver, kidney, and brain with respect to heat stability, optical specificity, inhibition by typical DOPA decarboxylase inhibitors, and activation by pyridoxal 5'-phosphate. In the present work, evidence has been obtained that the ability of erythrocyte hemolysates to decarboxylate DOPA is associated with an interaction between DOPA and methemoglobin in which methemoglobin is reduced and DOPA is decarboxylated. That the reaction may be of more general significance is indicated by the occurrence of an analogous reaction between DOPA and other ferriheme proteins. myoglobin, horse-heart cytochrome c, and horse-radish peroxidase were purchased from Schwarz-Mann. Human methemoglobin, and beef-liver catalase were obtained from Sigma. [1-'4C] and [2-14C] DL-DOPA, [ The activity of human kidney extracts was measured as described above, except that the assay solution also contained 5 mM 2-mercaptoethanol and 10 /AM pyridoxal 5'-phosphate. Controls contained heat-inactivated extracts.
The spectra were determined with a Cary model 15 spectrophotometer equipped with a water-jacketted cuvet compartment. Dopamine was determined as described by Hinten Extracts were prepared and assayed as described in the text. Activity is expressed as nmol of DOPA decarboxylated per 15 min per ml of hemolysate or per mg of kidney-extract protein.
thus, virtually all of the [14C]i-DOPA was decarboxylated. The reaction mixture was placed in a centrifuge tube, which was immersed in a boiling-water bath for 1 min. After the tube was cooled and centrifuged, 2 ml of the clear supernatant solution was withdrawn and D-DOPA was added to yield a final concentration of 0.01 M. The specific activity of the Other hemoproteins tested, such as horse-heart cytochrome c and peroxidase also promoted DOPA decarboxylation. Fig. 1 shows the effect of L-DOPA on the absorption spectrum of metmyoglobin. Curve 1 gives the spectrum of metmyoglobin; after incubation of metmyoglobin with DOPA in air, a spectrum characteristic of oxymyoglobin was obtained (Curve 2). The findings indicate that metmyoglobin is reduced to the ferrous form, which reacts rapidly with oxygen. Human methemoglobin gave substantially the same results in studies performed under similar conditions. In the experiment described in Fig. 2 , ferricytochrome c (Curve 1) was incubated with DOPA; the spectrum obtained (Curve 2) is characteristic of ferrocytochrome c. In the experiment described in Fig. 3 , sperm-whale metmyoglobin was incubated with L-DOPA; the reduction of metmyoglobin to the ferrous form and the decarboxylation of DOPA were determined. Under these conditions, there was a slow decarboxylation of DOPA in the absence of metmyoglobin; this occurred at about 15% of the rate found in the presence of metmyoglobin.
The data, thus, indicate that the presence of metmyoglobin increased the rate of DOPA decarboxylation by about 6-fold. As indicated in Fig. 3 , the extent of the rapid decarboxylation produced by metmyoglobin is about equivalent, within experimental error, to the conversion of metmyoglobin to the ferrous form. Similar results were obtained in experiments with 1.0 and 2.0 mg of metmyoglobin. In these experiments, formation of CO2 was slower than the reduction of metmyoglobin, suggesting that an intermediate is formed that is decarboxylated in a subsequent step. Analogous experiments with human methemoglobin led to similar results; thus, about 4 mol of iDOPA were decarboxylated per mol of methemoglobin, or about 1 mol of L-DOPA per mol of heme. These findings indicate that there is equivalence between the reduction of the ferriheme proteins and the amount of DOPA decarboxylated. The effect of ferriheme protein concentration on the rate of DOPA decarboxylation was examined (Fig. 4) ; the rate of decarboxylation increased with increased protein concentration, then leveled off. The findings suggest that the decarboxylation may occur in at least two steps, as discussed below.
We found that the decarboxylation of DOPA by metmyoglobin and methemoglobin is markedly inhibited by iascorbate. Thus, as indicated by the data given in Table 3 , 0.02 mM L-ascorbate inhibited decarboxylation by more than 70%, and 0.1 mAM L-ascorbate decreased decarboxylation by about 97%. It seems unlikely that the inhibition of DOPA decarboxylation by ascorbate under these conditions is due to reduction of ferriheme protein to ferroheme protein; thus, 0.1 mM iLascorbate reduced only 10% of the metmyoglobin under the conditions used in the experiments described in Table 3 . Products of the Reaction. Dopamine has been found in normal adult human erythrocytes (8) and also in the erythrocytes of patients with Parkinson's disease that receive therapy with L-DOPA (2). As noted earlier, human-blood serum does not exhibit DOPA decarboxylase activity (1) . In the present work, by procedures similar to those used by Hinterberger (2), we have confirmed the observation of Hinterberger (2) that [3H]dopamine is formed when [3H]-DOPA is incubated with human erythrocyte hemolysates. When commercial preparations of methemoglobin and metmyoglobin were incubated with [2-14C]DL-DOPA, only traces of dopamine could be detected by chromatography. Studies on experiments incubated for 1-4 hr at 370 showed the formation of melanin-like pigments that remained at the origin of the paper chromatograms; incubation of dopamine itself with metmyoglobin also led to the formation of such pigments. The findings indicate that while some dopamine is formed in this reaction, additional chemical transformation occurs that is associated with polymer formation. These observations are reminiscent of those of Green et al (9) , who showed that the reduction of methemoglobin and of ferricytochrome c by epinephrine is associated with the formation of adrenochrome, which undergoes additional transformation to yield melanin-like pigments. The present findings on the interaction of ferriheme proteins with DOPA do not exclude the possible occurrence of additional oxidative reactions of DOPA and dopamine.
DISCUSSION
The studies reported here, which confirm the earlier finding in this laboratory that hemolysates of human erythrocytes decarboxylate DOPA (1) , indicate that this decarboxylation is unusual in that it is not catalyzed by a pyridoxal 5'-phosphate-dependent enzyme. The DOPA-decarboxylating activity of erythrocytes is atypical with respect to heat stability, activation by pyridoxal 5'-phosphate, inhibition by certain inhibitors, and optical specificity. The findings indicate that the decarboxylation of DOPA is due to methemoglobin present. Thus, treatment with ferricyanide led to a marked increase in decarboxylase activity, and reduction with 2-mercaptoethanol or dithionite led to marked decreases. The spectral studies reported here indicate that the decarboxylation of DOPA is associated with reduction of the ferriheme protein to ferroheme protein. Presumably, this is accompanied by oxidation of DOPA to an intermediate, which might be a quinone or semiquinone that can undergo decarboxylation in a subsequent step. Such an intermediate would be expected to be reduced by ascorbate; a reaction of this type may explain the observed inhibition of decarboxylation by low concentrations of ascorbate.* We reported (1) a substantial decrease in DOPA-decarboxylase activity of erythrocytes obtained from patients with Parkinson's disease who received oral DOPA therapy. As stated previously, none of the patients studied was anemic; therefore, it seems improbable that these observations reflect a decrease in the total concentration of blood hemoglobin.
In the light of the present observations, the decreased DOPA decarboxylase activity of the erythrocytes of treated patients previously observed may probably be ascribed to a decrease in the small amount of methemoglobin normally present (10) by reduction by the administered DOPA. While the concentrations of methemoglobin and of metmyoglobin are probably normally quite low in vivo, the presence of even small amounts of these ferriheme proteins might be of considerable significance in relation to the production of dopamine in patients receiving very large doses of DOPA for the therapy of the Parkinson's disease. The finding that ferricytochrome c can be readily reduced by DOPA must also be considered in relation to the effects of therapy with massive doses of L-DOPA; such patients may have abnormalities of oxidative metabolism. These considerations, which require additional study, may be of significance in relation to some of the side effects of therapy with large oral doses of DOPA (11) . 
